Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study

1. Sehn, L.H.
2. Goy, A.
3. Offner, F.C.
4. Martinelli, G.
5. Caballero, M.D.
6. Gadeberg, O.
7. Baetz, T.
8. Zelenetz, A.D.
9. Gaidano, G.
10. Fayad, L.E.
11. Buckstein, R.
12. Friedberg, J.W.
13. Crump, M.
14. Jaksic, B.
15. Zinzani, P.L.
16. Iyer, S.P.
17. Sahin, D.
18. Chai, A.
19. Fingerle-Rowson, G.
20. Press, O.W.